Press Release
Shire plc News Alert Shire in-licenses JUVISTA(R) (human TGFâ3) from Renovo
20 June 2007
- Novel biopharmaceutical drug candidate for the prevention and reduction of scarring in connection with both therapeutic and cosmetic surgery – a market served by specialist physicians
- In-license includes exclusive worldwide rights except for EU member states
- Financial payments geared to success and linked to significant milestones
- Renovo estimates a potential new multi-billion market opportunity in the U.S.
Basingstoke, UK and Philadelphia, US – June 20, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today the signing of an agreement with Renovo Group plc (LSE: RNVO) for the exclusive development and commercialization rights to JUVISTA(R), Renovo’s novel treatment in late phase 2 development for the prevention and reduction of scarring. Phase 3 trials are anticipated to commence in mid 2008.
Under the terms of the agreement Shire has the exclusive right to commercialize JUVISTA worldwide, with the exception of EU member states.
To view the full announcement please visit our website http://www.shire.com and go to the Latest News.
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
